{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'The 8 domains of the SF-36 are as follows:', 'Vitality', 'Physical functioning', 'Bodily pain', 'General health perceptions', 'Physical role functioning', 'Emotional role functioning', 'Social role functioning', 'Mental health', '7.1.10.3 European Quality of Life - 5 Dimensions', 'The conceptual basis of the EQ-5D is the holistic view of health, including both the medical', 'definition and the fundamental importance of independent physical, emotional, and social', 'functioning. The concept of health in EQ-5D also encompasses both positive aspects', '(well-being) and negative aspects (illness).', 'The EQ-5D consists of a questionnaire and a VAS and is a self-rated health status. The', \"EQ-5D records the subject's perceptions of their own current overall health, and can be used\", 'to monitor changes with time. The self-assessment questionnaire is a description of', '5 dimensions (i.e., mobility, self-care, usual activities, pain/discomfort, and', 'anxiety/depression). The subject is asked to grade their own current level of function in each', 'dimension into 1 of 5 degrees of disability (extreme, severe, moderate, slight, or none). The', 'combination of these with the conditions \"death\" and \"unconscious\" enables a description of', '3127 different health states. Each health state can be ranked and transformed as a single', 'score called the utility.', 'The EQ-5D health states may be converted into a single summary index by applying a', 'formula that attaches values to each of the levels in each dimension. The index can be', 'calculated by deducting the appropriate weights from 1, the value for full health (i.e., state', '11111). Value sets have been derived for EQ-5D in several countries using the European', 'Quality of Life-5 Dimensions Visual Analog Scale (EQ-5D VAS) valuation technique or the', 'time trade-off valuation technique.', 'Amendment 2: 06 March 2019', '94', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '7.1.10.4 Work Productivity Survey - Rheumatoid Arthritis', 'The WPS-RA measures the impact of RA and treatment on subject productivity within and', 'outside the home during the previous month. It contains 9 questions addressing employment', 'status, productivity within and outside the home, and daily activities. One item of the', 'WPS-RA addresses current labor market participation. This is a strong indicator of work', 'ability because not working implies complete loss of paid productivity. There are also', 'normative and comparative data available on employment status. Two items capture', 'self-reported work absences due to arthritis, and 2 items capture the same concept but applied', 'to non-paid work. These are separated into full and partial days (i.e., days of work missed', 'and days with productivity reduced by at least half). Additional items capture the', \"respondent's estimate of the extent to which arthritis has interfered with the subject's work\", 'productivity (paid and non-paid) on a scale of 0 to 10, the number of days in the last month', 'outside help was hired because of arthritis, and the number of days in the last month family,', 'social, or leisure activities were missed because of arthritis.', '7.1.10.5 Functional Assessment of Chronic Illness Therapy - Fatigue Scale', \"FACIT-Fatigue is a 13-item tool that measures an individual's level of fatigue during their\", 'usual daily activities during the most recent week. The level of fatigue is measured on a', '4-point Likert scale.', 'The sum of the scoring (total score) will be used for the statistical evaluation. If an item is', 'not scored, the total score will be set to missing.', '7.2 Pharmacokinetics', 'There will be no collection of blood samples for the determination of OKZ concentration in', 'plasma in this study.', 'The Week 24 sample is the last sample to be collected in the core studies. This sample', 'must be collected prior to administration of OKZ in the OLE study, and the sample', 'will be analyzed and included in the data set of the core study in which the subject', 'participated, according to the procedures detailed in the core study protocol. This', 'sample will not be analyzed as part of the OLE data set.', 'To provide documentation that the Week 24 PK sample was collected prior to the first dose', 'of study treatment in this study, the date and time of OKZ administration at Week 24 will be', \"captured in each subject's eCRF.\", 'Although there will be no collection of blood samples in this study for the determination of', 'OKZ concentration in plasma, blood samples that are collected for immunogenicity analysis', '(see Section 7.3) may also be used to determine OKZ concentrations in plasma if it is', 'Amendment 2: 06 March 2019', '95', 'Confidential']\n\n###\n\n", "completion": "END"}